Infusion Pumps Market Size and Share Analysis by Product Type (Devices, Accessories and Consumables), Functionality (Specialty, Traditional), Application (Chemotherapy/Oncology, Diabetes Management, Gastroenterology, Pain Management/Analgesia, Pediatrics/Neonatology), End User (Hospitals, Homecare Settings, Ambulatory Care Settings) - Forecast to 2030

Market Overview

The infusion pumps market generated a revenue of $12,825.9 million in 2021, and it is expected to grow at a CAGR of 8.7% during 2021–2030, to reach $27,133.7 million by 2030. Factors including the rising prevalence of chronic diseases, increasing popularity of home infusion treatments, growing elderly population, surging cases of hospital-acquired illnesses, and technological developments are responsible for the market expansion. For instance:

• As per the National Cancer Institute (NCI), there will be more than 26 million cancer survivors in the U.S. by 2040.
• Additionally, the number of new cancer cases is expected to rise by around 30 million each year across the world.

During the COVID-19 pandemic, to prevent the virus spread, remote monitoring of patients and usage of medications were increased, which boosted the demand for infusion pumps. In addition, the FDA approved an umbrella EUA for infusion pumps and infusion pump accessories on May 13, 2020. It has been used by healthcare professionals to treat COVID-19-related complications with regulated infusions of medicines, complete parenteral nutrition, or other fluids.

Increasing Number of Partnerships and Collaborations Is a Prime Market Trend

Companies in the market have been actively involved in partnerships and collaborations for developing advanced solutions. This is reported as one of the major trends in this market. Some of the recent collaborations and partnerships reported in the industry are:

• In February 2022, American Oncology Network LLC collaborated with InfuSystem Holdings Inc.
• In November 2021, Zealand Pharma and DEKA Research & Development Corp. entered into a collaboration agreement to advance the development of infusion pumps.
• In July 2021, Smiths Medical partnered with Ivenix Inc.
• In August 2019, Eitan Group announced a service partnership with InfuSystem Holdings Inc.

Accessories and Consumables Held Larger Share in the Market

The accessories and consumables category held a larger share in the infusion pumps market in 2021. This is primarily due to the availability of a broad range of accessories and consumables and their repetitive purchases, across the globe.

The devices category accounted for around 45% market share in 2021. There are several types of devices, such as insulin pumps, volumetric infusion pumps, enteral infusion pumps, implantable infusion pumps, ambulatory infusion pumps, syringe infusion pumps, and PCA pumps. Among these, the insulin pumps category dominated the market in 2021 and it is expected to maintain the same trend in the upcoming years as well. This is majorly attributed to the reliability of the pumps over others and their high availability. Furthermore, several awareness programs with respect to diabetes across the world are promoting diabetes care among citizens, which will further propel the insulin pumps market growth in the coming years.

Demand for Traditional Infusion Pumps To Grow Faster

The demand for traditional infusion pumps is projected to witness faster growth, advancing at a CAGR of around 10%, during the forecast period. This can be because the demand for these pumps is increasing for delivering pain medicines, antibiotics, chemotherapeutic drugs, and hydration fluids, in-home and long-term care settings.

Diabetes Management Application Dominated the Market

The diabetes management category accounted for the largest revenue share, over 30%, in the market in 2021. This is attributed to the growing prevalence of diabetes and its complications across the globe. Furthermore, innovations in diabetes management wearable technology and extended infusion period are also responsible for the major adoption of these systems. For instance:

• In April 2021, Medtronic plc launched its new technology of a wearable infusion set in the European market, highlighting wear time up to 7 days.
• In May 2021, Roche Holding AG announced the approval of the Accu-Chek Insight insulin pump with the automated insulin delivery (AID) system from Diabeloop in Switzerland.

Such innovations and product developments are accountable for the market growth in this category.

Growing Significance of Home Infusion Therapy for Diabetes Treatment Aiding the Market Growth

With the surging emphasis on cost-effectiveness in the healthcare sector, there is a continuous shift of patients from expensive healthcare settings, including emergency and other hospital departments, to less-costly alternative sites, such as diabetes clinics/centers and home care settings. Such alternative healthcare settings offer greater convenience. Due to the rising availability of advanced insulin delivery devices, home infusion therapy is rapidly gaining acceptance among diabetic patients. Moreover, infusion insulin pumps provide an accurate dosage of insulin throughout the day; therefore, the popularity of home infusion therapy has grown significantly, globally.

Home Care Settings Category To Witness the Fastest Growth

The home care settings category accounted for a revenue share of around 30% in 2021 in the infusion pumps market, and it is expected to grow at the highest growth rate during the forecast period. The increased prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory diseases; high cost of hospitalization; and growth in the elderly population and patient pool are key factors for the rapid market expansion in this category.

Explore more about this report - Request free sample

North America Leads the Market

North America is the largest market for infusion pumps, globally, followed by Europe. The dominance of the regional market is due to the presence of well-developed healthcare infrastructure, high acceptance of technologically improved products, and growth in the geriatric population.

Moreover, in Europe, diabetes is becoming more common among people of all ages. Around 35 million adults were diagnosed with diabetes in 2019, up from 17 million persons in 2000 in the EU. An additional 25 million diabetic people in Europe were undiagnosed in 2019. The number of males diagnosed with diabetes doubled during 2000–2019, increasing from roughly 7.3 million in 2000 to 16.7 million in 2019. Therefore, the need for providing cost-effective and better healthcare solutions and services to the increasing diabetic population has raised the demand for insulin delivery devices in the region.

Furthermore, the APAC market has witnessed significant growth in recent years and is projected to continue to do so in the coming years. The regional market is growing mainly due to the surging prevalence of lifestyle diseases including diabetes and obesity, the rising awareness about diabetes management, and the increasing healthcare spending. Moreover, expanding government efforts, particularly in populous countries like China and India, development in the field of contemporary healthcare infrastructure, and increasing understanding about the use of infusion pumps are further propelling the market in the region.

Market Players Are Engaged in Acquisitions to Improve their Position

The infusion pumps market is competitive, due to the presence of several major players. These players have been increasingly engaging in acquisitions to strengthen their position. For instance:

• In January 2022, ICU Medical Inc. announced the acquisition of Smiths Medical from Smiths Group plc, which includes syringes and ambulatory infusion devices, vascular access, and vital care products.
• In December 2019, Medtronic plc acquired Klue, a software company focused on behavior tracking that can provide real-time insights into when a person is eating. Klue's technology would be used in the Medtronic Personalized Closed Loop (PCL) insulin pump system.

Key Players in the Market Are:

• Baxter International Inc.
• Becton, Dickinson and Company
• Braun Melsungen AG
• CareFusion Corporation
• Medtronic Inc.
• ICU Medical Inc.
• Nipro Corporation
• Pfizer Inc.
• Terumo Corporation
• Eli Lilly and Company

Market Size Breakdown by Segment

The report offers comprehensive market segmentation analysis along with the revenue estimation for the period 2017–2030.

Based on Product Type

• Devices
  • Volumetric
  • Insulin
  • Enteral
  • Syringe
  • Ambulatory
  • Patient-controlled analgesia (PCA)
  • Implantable
• Accessories and Consumables

Based on Functionality

• Specialty
• Traditional

Based on Application

• Chemotherapy/Oncology
• Diabetes Management
• Gastroenterology
• Pain Management/Analgesia
• Pediatrics/Neonatology

Based on End User

• Hospitals
• Homecare Settings
• Ambulatory Care Settings

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • Spain
  • U.K.
  • Italy
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America (LATAM)
  • Brazil
  • Mexico
• Middle East and Africa (MEA)
  • Saudi Arabia
  • South Africa